プロテアソーム阻害剤の世界市場レポート 2025年

プロテアソーム阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.9％で32億米ドルに成長します。予測期間の成長は、精密医療へのアプローチ、次世代阻害剤、ヘルスケアインフラの成長、標的療法の組み合わせ、新興市場の採用に起因すると考えられます。予測期間の主な動向には、免疫療法の併用、選択的プロテアソーム阻害、半減期の長い阻害剤、経口製剤、耐性がん変種治療などがあります。

膵臓がんの有病率の増加は、今後のプロテアソーム阻害剤市場の拡大を牽引すると予測されます。膵臓がんは、胃の後ろの腹部に位置する臓器である膵臓の細胞にがんが発生することで発症します。プロテアソームは、細胞周期の進行とアポトーシスを制御するタンパク質を分解することにより、細胞の生存と成長を促進する重要な役割を果たしているため、プロテアソーム阻害剤は主に膵臓がんの治療に利用されています。がん細胞の生存を阻害することで、これらの阻害剤は腫瘍の成長と転移を妨げます。例えば、2024年1月、米国を拠点とする健康団体である米国がん協会からの報告によると、2023年に米国の成人約64,050人が膵臓がんと診断され、50,550人が死亡しました。さらに、この数は66,440例まで増加し、死亡者数は51,750人に増加すると予測されています。したがって、膵臓がんの有病率の上昇がプロテアソーム阻害剤市場の成長を促進しています。

プロテアソーム阻害剤市場の成長は、研究開発に対する政府資金の増加によってさらに促進されます。政府資金は、科学的調査、臨床試験、医薬品開発を財政的に支援することで、プロテアソーム阻害剤の研究を進める上で重要な役割を果たしています。例えば、米国の国立がん研究所は、2023会計年度に73億米ドルの予算を獲得しており、2022年よりも4億800万米ドル増加しています。このような大幅な資金援助は、プロテアソーム阻害剤市場の成長促進に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のプロテアソーム阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のプロテアソーム阻害剤市場：成長率分析
• 世界のプロテアソーム阻害剤市場の実績：規模と成長, 2019-2024
• 世界のプロテアソーム阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界のプロテアソーム阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のプロテアソーム阻害剤市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベルケイド
• キプロリス
• ニンラロ
• その他の製品
• 世界のプロテアソーム阻害剤市場：薬物別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ボルテゾミブ
• カルフィルゾミブ
• イキサゾミブ
• 世界のプロテアソーム阻害剤市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リンパ腫
• マントル細胞リンパ腫
• 多発性骨髄腫
• 世界のプロテアソーム阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のプロテアソーム阻害剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界のプロテアソーム阻害剤市場、ベルケイドのサブセグメンテーション、製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用ベルケイド（ボルテゾミブ）
• 経口製剤
• 世界のプロテアソーム阻害剤市場、キプロリスのサブセグメンテーション、製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用キプロリス（カルフィルゾミブ）
• カイプロリスとの併用療法
• 世界のプロテアソーム阻害剤市場、ニンラロのサブセグメンテーション、製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口ニンラロ（イキサゾミブ）
• ニンラロとの併用療法
• 世界のプロテアソーム阻害剤市場、その他の製品のサブセグメンテーション、製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 研究プロテアソーム阻害剤
• 併用製品

第7章 地域別・国別分析

• 世界のプロテアソーム阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のプロテアソーム阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• プロテアソーム阻害剤市場：競合情勢
• プロテアソーム阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• Thermo Fisher Scientific Inc.
• AstraZeneca Plc
• Fresenius Kabi AG
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Baxter International Inc.
• Sigma-Aldrich
• Zydus Pharmaceuticals
• Onyx Pharmaceuticals Inc.
• Tocris Bioscience
• Accuitis Inc.
• TG Therapeuticsn Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• プロテアソーム阻害剤市場2029：新たな機会を提供する国
• プロテアソーム阻害剤市場2029：新たな機会を提供するセグメント
• プロテアソーム阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Proteasome inhibitors constitute a class of drugs designed to disrupt the activity of proteasomes, cellular complexes responsible for the regulated degradation of proteins. These inhibitors find primary application in the treatment of specific types of cancer, particularly multiple myeloma, and certain forms of lymphoma. They have demonstrated significant efficacy in targeting cancer cells and inducing cell death.

The main types of products in proteasome inhibitors include Velcade, Kyprolis, Ninlaro, and others. Velcade, for instance, is the brand name for the prescription drug bortezomib. Bortezomib, as a proteasome inhibitor, is utilized in the treatment of multiple myeloma cancer. Various drugs fall under this category, such as bortezomib, carfilzomib, and ixazomib. Proteasome inhibitors are employed to treat diverse indications, including lymphoma, mantle cell lymphoma, and multiple myeloma. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, with end-users primarily consisting of hospitals, specialty clinics, and others.

The proteasome inhibitors market research report is one of a series of new reports from The Business Research Company that provides proteasome inhibitors market statistics, including proteasome inhibitors industry global market size, regional shares, competitors with a proteasome inhibitors market share, detailed proteasome inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the proteasome inhibitors industry. This proteasome inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proteasome inhibitors market size has grown strongly in recent years. It will grow from $2.01 billion in 2024 to $2.19 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to scientific breakthroughs, clinical research and trials, FDA approvals, rising cancer cases, advancements in drug delivery

The proteasome inhibitors market size is expected to see strong growth in the next few years. It will grow to $3.2 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to precision medicine approaches, next-generation inhibitors, healthcare infrastructure growth, targeted therapies combination, emerging markets adoption. Major trends in the forecast period include immunotherapy combinations, selective proteasome inhibition, longer half-life inhibitors, oral formulations, resistant cancer variant treatments.

The growing prevalence of pancreatic cancer is anticipated to drive the expansion of the proteasome inhibitors market in the future. Pancreatic cancer occurs when cancer develops in the cells of the pancreas, an organ situated in the abdomen behind the stomach. Proteasome inhibitors are primarily utilized in the treatment of pancreatic cancer, as the proteasome plays a vital role in promoting cell survival and growth by degrading proteins that regulate cell cycle progression and apoptosis. By disrupting cancer cell survival, these inhibitors hinder tumor growth and metastasis. For instance, in January 2024, reports from the American Cancer Society, a US-based health organization, indicated that approximately 64,050 adults in the US were diagnosed with pancreatic cancer in 2023, resulting in 50,550 deaths. Additionally, this number is projected to rise to 66,440 diagnosed cases, with deaths increasing to 51,750. Therefore, the rising prevalence of pancreatic cancer is propelling the growth of the proteasome inhibitors market.

The growth of the proteasome inhibitors market is further propelled by increasing government funding for research and development. Government funding plays a crucial role in advancing proteasome inhibitor research by financially supporting scientific investigations, clinical trials, and drug development. For example, the National Cancer Institute in the US received a budget of $7.3 billion in fiscal year 2023, a $408 million increase over 2022. This substantial funding boost contributes to driving the growth of the proteasome inhibitors market.

Investments are emerging as a key trend in the proteasome inhibitors market, with major companies investing in the development and commercialization of these inhibitors. In September 2022, QLi5 Therapeutics GmbH, a Germany-based developer of novel proteasome inhibitors, secured a significant investment of $10.96 million from venture capital firms such as SV Investment, KHAN Technology Transfer Fund I, Atinum Investment Co., Ltd., and Daol Investment & Securities Co., Ltd. This funding supports QLi5's efforts to advance its pipeline of distinct proteasome inhibitors for cancer, inflammatory, and autoimmune disorders, contributing to the market's growth.

Major companies in the proteasome inhibitor market are intensifying their efforts to develop novel generic medications, such as single-dose vials, to secure a competitive advantage. A single-dose vial is a sealed container, usually made of glass, that holds a single dose of medication intended for parenteral administration, which means it is delivered through injection or infusion. For example, in July 2022, Dr. Reddy's Laboratories, a pharmaceutical company based in India, launched Bortezomib for Injection, 3.5 mg, in the U.S. market. This product serves as the generic equivalent of Velcade (bortezomib) injection, having received approval from the U.S. Food and Drug Administration (USFDA). Bortezomib is indicated for adult patients diagnosed with multiple myeloma and is available in a 3.5 mg per 10 mL single-dose vial format for subcutaneous (SQ) or intravenous (IV) administration.

In October 2022, Karyopharm Therapeutics Inc., a US-based pharmaceutical company, collaborated with Bristol-Myers Squibb to assess mezigdomide in patients who have received previous treatments. This collaboration with Bristol-Myers Squibb, a provider of innovative medicines, demonstrates a strategic approach to advancing research and development in the proteasome inhibitors market.

Major companies operating in the proteasome inhibitors market include Pfizer Inc., Johnson And Johnson, AbbVie, Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Fresenius Kabi AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Sigma-Aldrich, Zydus Pharmaceuticals, Onyx Pharmaceuticals Inc., Tocris Bioscience, Accuitis Inc., TG Therapeuticsn Inc., QLi5 Therapeutics GmbH, Progenra Inc., Nurix Inc., Cephalon Inc., Cleave Therapeutics, Lifesensors Inc., MimiVax LLC, Apotex Inc.

North America was the largest region in the proteasome inhibitors market in 2024. The regions covered in the proteasome inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the proteasome inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The proteasome inhibitor market consists of sales of marizomib, oprozomib, and delanzomib, epoxyketone proteasome inhibitors, non-peptidic proteasome inhibitors, panobinostat and olaparib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Proteasome Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on proteasome inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for proteasome inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The proteasome inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Velcade; Kyprolis; Ninlaro; Other Products
• 2) By Drugs: Bortezomib; Carfilzomib; Ixazomib
• 3) By Indication: Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End-User: Hospital; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Velcade: Injectable Velcade (Bortezomib); Oral Formulations
• 2) By Kyprolis: Injectable Kyprolis (Carfilzomib); Combination Therapies With Kyprolis
• 3) By Ninlaro: Oral Ninlaro (Ixazomib); Combination Therapies With Ninlaro
• 4) By Other Products: Investigational Proteasome Inhibitors; Combination Products
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson; AbbVie; Novartis AG; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Proteasome Inhibitors Market Characteristics

3. Proteasome Inhibitors Market Trends And Strategies

4. Proteasome Inhibitors Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Proteasome Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Proteasome Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Proteasome Inhibitors Market Growth Rate Analysis
• 5.4. Global Proteasome Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Proteasome Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Proteasome Inhibitors Total Addressable Market (TAM)

6. Proteasome Inhibitors Market Segmentation

• 6.1. Global Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Velcade
• Kyprolis
• Ninlaro
• Other Products
• 6.2. Global Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bortezomib
• Carfilzomib
• Ixazomib
• 6.3. Global Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• 6.4. Global Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Specialty Clinics
• Other End-Users
• 6.6. Global Proteasome Inhibitors Market, Sub-Segmentation Of Velcade, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Velcade (Bortezomib)
• Oral Formulations
• 6.7. Global Proteasome Inhibitors Market, Sub-Segmentation Of Kyprolis, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Kyprolis (Carfilzomib)
• Combination Therapies With Kyprolis
• 6.8. Global Proteasome Inhibitors Market, Sub-Segmentation Of Ninlaro, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Ninlaro (Ixazomib)
• Combination Therapies With Ninlaro
• 6.9. Global Proteasome Inhibitors Market, Sub-Segmentation Of Other Products, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Investigational Proteasome Inhibitors
• Combination Products

7. Proteasome Inhibitors Market Regional And Country Analysis

• 7.1. Global Proteasome Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Proteasome Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Proteasome Inhibitors Market

• 8.1. Asia-Pacific Proteasome Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Proteasome Inhibitors Market

• 9.1. China Proteasome Inhibitors Market Overview
• 9.2. China Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Proteasome Inhibitors Market

• 10.1. India Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Proteasome Inhibitors Market

• 11.1. Japan Proteasome Inhibitors Market Overview
• 11.2. Japan Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Proteasome Inhibitors Market

• 12.1. Australia Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Proteasome Inhibitors Market

• 13.1. Indonesia Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Proteasome Inhibitors Market

• 14.1. South Korea Proteasome Inhibitors Market Overview
• 14.2. South Korea Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Proteasome Inhibitors Market

• 15.1. Western Europe Proteasome Inhibitors Market Overview
• 15.2. Western Europe Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Proteasome Inhibitors Market

• 16.1. UK Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Proteasome Inhibitors Market

• 17.1. Germany Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Proteasome Inhibitors Market

• 18.1. France Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Proteasome Inhibitors Market

• 19.1. Italy Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Proteasome Inhibitors Market

• 20.1. Spain Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Proteasome Inhibitors Market

• 21.1. Eastern Europe Proteasome Inhibitors Market Overview
• 21.2. Eastern Europe Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Proteasome Inhibitors Market

• 22.1. Russia Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Proteasome Inhibitors Market

• 23.1. North America Proteasome Inhibitors Market Overview
• 23.2. North America Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Proteasome Inhibitors Market

• 24.1. USA Proteasome Inhibitors Market Overview
• 24.2. USA Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Proteasome Inhibitors Market

• 25.1. Canada Proteasome Inhibitors Market Overview
• 25.2. Canada Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Proteasome Inhibitors Market

• 26.1. South America Proteasome Inhibitors Market Overview
• 26.2. South America Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Proteasome Inhibitors Market

• 27.1. Brazil Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Proteasome Inhibitors Market

• 28.1. Middle East Proteasome Inhibitors Market Overview
• 28.2. Middle East Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Proteasome Inhibitors Market

• 29.1. Africa Proteasome Inhibitors Market Overview
• 29.2. Africa Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Proteasome Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Proteasome Inhibitors Market Competitive Landscape
• 30.2. Proteasome Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Proteasome Inhibitors Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Thermo Fisher Scientific Inc.
• 31.3. AstraZeneca Plc
• 31.4. Fresenius Kabi AG
• 31.5. GlaxoSmithKline PLC
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Baxter International Inc.
• 31.10. Sigma-Aldrich
• 31.11. Zydus Pharmaceuticals
• 31.12. Onyx Pharmaceuticals Inc.
• 31.13. Tocris Bioscience
• 31.14. Accuitis Inc.
• 31.15. TG Therapeuticsn Inc.

32. Global Proteasome Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Proteasome Inhibitors Market

34. Recent Developments In The Proteasome Inhibitors Market

35. Proteasome Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Proteasome Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Proteasome Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Proteasome Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer